+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Melanoma Drug Market Research Report by Type of Melanoma (Acral Lentiginous Melanoma, Lentigo Maligna Melanoma, and Nodular Melanoma), Therapy, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 4968662
  • Report
  • April 2022
  • Region: Global
  • 215 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022
The Global Melanoma Drug Market size was estimated at USD 4,323.70 million in 2021, USD 4,889.77 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 13.26% to reach USD 9,131.19 million by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Melanoma Drug to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Type of Melanoma, the market was studied across Acral Lentiginous Melanoma, Lentigo Maligna Melanoma, Nodular Melanoma, and Superficial Spreading Melanoma.
  • Based on Therapy, the market was studied across Chemotherapy, Immunotherapy, and Targeted Therapy.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.

This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Melanoma Drug market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Melanoma Drug Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Melanoma Drug Market, including AB Sciences, AbbVie Inc., Amgen, Aptose Biosciences, Array BioPharma, AstraZeneca, AVAX Technologies, Biogen, Bristol-Myers Squibb, Celgene, CK Life Sciences Int’l, Daiichi Sankyo Company, Limited, Eli Lilly, Enzon Pharmaceuticals Inc., Genentech, GlaxoSmithKline plc, Incyte, Janssen Biotech, Johnson & Johnson, Merck & Co., Novartis, ONO PHARMACEUTICAL CO. LTD, Pantarhei Bioscience, Philogen, Pierre Fabre, Polynoma, Provectus, Reliance Industries Limited, Roche, Sanofi, Schering-Plough, and Takeda Pharmaceutical.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Melanoma Drug Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Melanoma Drug Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Melanoma Drug Market?
4. What is the competitive strategic window for opportunities in the Global Melanoma Drug Market?
5. What are the technology trends and regulatory frameworks in the Global Melanoma Drug Market?
6. What is the market share of the leading vendors in the Global Melanoma Drug Market?
7. What modes and strategic moves are considered suitable for entering the Global Melanoma Drug Market?
Frequently Asked Questions about the Global Melanoma Drug Market

What is the estimated value of the Global Melanoma Drug Market?

The Global Melanoma Drug Market was estimated to be valued at $4323.7 Million in 2021.

What is the growth rate of the Global Melanoma Drug Market?

The growth rate of the Global Melanoma Drug Market is 13.2%, with an estimated value of $9131.2 Million by 2027.

What is the forecasted size of the Global Melanoma Drug Market?

The Global Melanoma Drug Market is estimated to be worth $9131.2 Million by 2027.

Who are the key companies in the Global Melanoma Drug Market?

Key companies in the Global Melanoma Drug Market include AB Sciences, AbbVie Inc., Amgen, Aptose Biosciences, Array BioPharma, AstraZeneca, AVAX Technologies, Biogen and Myers Squibb.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of melanoma and other skin cancers globally
5.1.1.2. Increasing patent expiration leading to use of biosimilars
5.1.1.3. Growing need for cost-effective therapeutics in developing regions
5.1.2. Restraints
5.1.2.1. Dearth of innovative and successful therapies
5.1.3. Opportunities
5.1.3.1. Emerging demand for targeted therapy owing to reduced side effects and higher efficiency
5.1.3.2. Ongoing research and development activities to introduce effective drugs
5.1.4. Challenges
5.1.4.1. Stringent regulatory policies and lengthy approval process
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of 2022 Russia Ukraine Conflict
6. Melanoma Drug Market, by Type of Melanoma
6.1. Introduction
6.2. Acral Lentiginous Melanoma
6.3. Lentigo Maligna Melanoma
6.4. Nodular Melanoma
6.5. Superficial Spreading Melanoma
7. Melanoma Drug Market, by Therapy
7.1. Introduction
7.2. Chemotherapy
7.3. Immunotherapy
7.4. Targeted Therapy
8. Americas Melanoma Drug Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Melanoma Drug Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
10. Europe, Middle East & Africa Melanoma Drug Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. AB Sciences
12.2. AbbVie Inc.
12.3. Amgen
12.4. Aptose Biosciences
12.5. Array BioPharma
12.6. AstraZeneca
12.7. AVAX Technologies
12.8. Biogen
12.9. Bristol-Myers Squibb
12.10. Celgene
12.11. CK Life Sciences Int’l
12.12. Daiichi Sankyo Company, Limited
12.13. Eli Lilly
12.14. Enzon Pharmaceuticals Inc.
12.15. Genentech
12.16. GlaxoSmithKline plc
12.17. Incyte
12.18. Janssen Biotech
12.19. Johnson & Johnson
12.20. Merck & Co.
12.21. Novartis
12.22. ONO PHARMACEUTICAL CO. LTD
12.23. Pantarhei Bioscience
12.24. Philogen
12.25. Pierre Fabre
12.26. Polynoma
12.27. Provectus
12.28. Reliance Industries Limited
12.29. Roche
12.30. Sanofi
12.31. Schering-Plough
12.32. Takeda Pharmaceutical
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL MELANOMA DRUG MARKET: DYNAMICS
FIGURE 2. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2021 VS 2027 (%)
FIGURE 3. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2021 VS 2027 (USD MILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2027
FIGURE 5. GLOBAL MELANOMA DRUG MARKET SIZE, BY ACRAL LENTIGINOUS MELANOMA, 2019-2027 (USD MILLION)
FIGURE 6. GLOBAL MELANOMA DRUG MARKET SIZE, BY ACRAL LENTIGINOUS MELANOMA, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 7. GLOBAL MELANOMA DRUG MARKET SIZE, BY LENTIGO MALIGNA MELANOMA, 2019-2027 (USD MILLION)
FIGURE 8. GLOBAL MELANOMA DRUG MARKET SIZE, BY LENTIGO MALIGNA MELANOMA, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 9. GLOBAL MELANOMA DRUG MARKET SIZE, BY NODULAR MELANOMA, 2019-2027 (USD MILLION)
FIGURE 10. GLOBAL MELANOMA DRUG MARKET SIZE, BY NODULAR MELANOMA, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 11. GLOBAL MELANOMA DRUG MARKET SIZE, BY SUPERFICIAL SPREADING MELANOMA, 2019-2027 (USD MILLION)
FIGURE 12. GLOBAL MELANOMA DRUG MARKET SIZE, BY SUPERFICIAL SPREADING MELANOMA, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 13. GLOBAL MELANOMA DRUG MARKET SIZE, BY THERAPY, 2021 VS 2027 (%)
FIGURE 14. GLOBAL MELANOMA DRUG MARKET SIZE, BY THERAPY, 2021 VS 2027 (USD MILLION)
FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MELANOMA DRUG MARKET SIZE, BY THERAPY, 2027
FIGURE 16. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY, 2019-2027 (USD MILLION)
FIGURE 17. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 18. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY, 2019-2027 (USD MILLION)
FIGURE 19. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 20. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY, 2019-2027 (USD MILLION)
FIGURE 21. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 22. AMERICAS MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 23. ARGENTINA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 24. BRAZIL MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 25. CANADA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 26. MEXICO MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 27. UNITED STATES MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 28. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 29. AUSTRALIA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 30. CHINA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 31. INDIA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 32. INDONESIA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 33. JAPAN MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 34. MALAYSIA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 35. PHILIPPINES MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 36. SINGAPORE MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 37. SOUTH KOREA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 38. TAIWAN MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 39. THAILAND MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 40. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 41. FRANCE MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 42. GERMANY MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 43. ITALY MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 44. NETHERLANDS MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 45. QATAR MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 46. RUSSIA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 47. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 48. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 49. SPAIN MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 50. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 51. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 52. GLOBAL MELANOMA DRUG MARKET: FPNV POSITIONING MATRIX
FIGURE 53. GLOBAL MELANOMA DRUG MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 54. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL MELANOMA DRUG MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL MELANOMA DRUG MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2019-2027 (USD MILLION)
TABLE 4. GLOBAL MELANOMA DRUG MARKET SIZE, BY ACRAL LENTIGINOUS MELANOMA, BY REGION, 2019-2027 (USD MILLION)
TABLE 5. AMERICAS MELANOMA DRUG MARKET SIZE, BY ACRAL LENTIGINOUS MELANOMA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 6. UNITED STATES MELANOMA DRUG MARKET SIZE, BY ACRAL LENTIGINOUS MELANOMA, BY STATE, 2019-2027 (USD MILLION)
TABLE 7. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY ACRAL LENTIGINOUS MELANOMA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 8. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY ACRAL LENTIGINOUS MELANOMA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 9. GLOBAL MELANOMA DRUG MARKET SIZE, BY LENTIGO MALIGNA MELANOMA, BY REGION, 2019-2027 (USD MILLION)
TABLE 10. AMERICAS MELANOMA DRUG MARKET SIZE, BY LENTIGO MALIGNA MELANOMA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 11. UNITED STATES MELANOMA DRUG MARKET SIZE, BY LENTIGO MALIGNA MELANOMA, BY STATE, 2019-2027 (USD MILLION)
TABLE 12. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY LENTIGO MALIGNA MELANOMA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 13. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY LENTIGO MALIGNA MELANOMA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 14. GLOBAL MELANOMA DRUG MARKET SIZE, BY NODULAR MELANOMA, BY REGION, 2019-2027 (USD MILLION)
TABLE 15. AMERICAS MELANOMA DRUG MARKET SIZE, BY NODULAR MELANOMA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 16. UNITED STATES MELANOMA DRUG MARKET SIZE, BY NODULAR MELANOMA, BY STATE, 2019-2027 (USD MILLION)
TABLE 17. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY NODULAR MELANOMA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 18. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY NODULAR MELANOMA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 19. GLOBAL MELANOMA DRUG MARKET SIZE, BY SUPERFICIAL SPREADING MELANOMA, BY REGION, 2019-2027 (USD MILLION)
TABLE 20. AMERICAS MELANOMA DRUG MARKET SIZE, BY SUPERFICIAL SPREADING MELANOMA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 21. UNITED STATES MELANOMA DRUG MARKET SIZE, BY SUPERFICIAL SPREADING MELANOMA, BY STATE, 2019-2027 (USD MILLION)
TABLE 22. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY SUPERFICIAL SPREADING MELANOMA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 23. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY SUPERFICIAL SPREADING MELANOMA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 24. GLOBAL MELANOMA DRUG MARKET SIZE, BY THERAPY, 2019-2027 (USD MILLION)
TABLE 25. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2019-2027 (USD MILLION)
TABLE 26. AMERICAS MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 27. UNITED STATES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY, BY STATE, 2019-2027 (USD MILLION)
TABLE 28. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 29. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 30. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2019-2027 (USD MILLION)
TABLE 31. AMERICAS MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 32. UNITED STATES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY, BY STATE, 2019-2027 (USD MILLION)
TABLE 33. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 34. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 35. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2019-2027 (USD MILLION)
TABLE 36. AMERICAS MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 37. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY, BY STATE, 2019-2027 (USD MILLION)
TABLE 38. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 39. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 40. AMERICAS MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 41. ARGENTINA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 42. BRAZIL MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 43. CANADA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 44. MEXICO MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 45. UNITED STATES MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 46. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 47. AUSTRALIA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 48. CHINA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 49. INDIA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 50. INDONESIA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 51. JAPAN MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 52. MALAYSIA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 53. PHILIPPINES MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 54. SINGAPORE MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 55. SOUTH KOREA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 56. TAIWAN MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 57. THAILAND MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 58. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 59. FRANCE MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 60. GERMANY MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 61. ITALY MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 62. NETHERLANDS MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 63. QATAR MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 64. RUSSIA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 65. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 66. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 67. SPAIN MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 68. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 69. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 70. GLOBAL MELANOMA DRUG MARKET: SCORES
TABLE 71. GLOBAL MELANOMA DRUG MARKET: BUSINESS STRATEGY
TABLE 72. GLOBAL MELANOMA DRUG MARKET: PRODUCT SATISFACTION
TABLE 73. GLOBAL MELANOMA DRUG MARKET: RANKING
TABLE 74. GLOBAL MELANOMA DRUG MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 75. GLOBAL MELANOMA DRUG MARKET: MERGER & ACQUISITION
TABLE 76. GLOBAL MELANOMA DRUG MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 77. GLOBAL MELANOMA DRUG MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 78. GLOBAL MELANOMA DRUG MARKET: INVESTMENT & FUNDING
TABLE 79. GLOBAL MELANOMA DRUG MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 80. GLOBAL MELANOMA DRUG MARKET: LICENSE & PRICING

Companies Mentioned

  • AB Sciences
  • AbbVie Inc.
  • Amgen
  • Aptose Biosciences
  • Array BioPharma
  • AstraZeneca
  • AVAX Technologies
  • Biogen
  • Bristol-Myers Squibb
  • Celgene
  • CK Life Sciences Int’l
  • Daiichi Sankyo Company, Limited
  • Eli Lilly
  • Enzon Pharmaceuticals Inc.
  • Genentech
  • GlaxoSmithKline plc
  • Incyte
  • Janssen Biotech
  • Johnson & Johnson
  • Merck & Co.
  • Novartis
  • ONO PHARMACEUTICAL CO. LTD
  • Pantarhei Bioscience
  • Philogen
  • Pierre Fabre
  • Polynoma
  • Provectus
  • Reliance Industries Limited
  • Roche
  • Sanofi
  • Schering-Plough
  • Takeda Pharmaceutical

Methodology

Loading
LOADING...